ClinicalTrials.gg
CompletedNCT02255552PROMOVIUpdated Jan 25, 2021Results posted

Study of Eteplirsen in DMD Patients

A Phase 3 interventional study of eteplirsen in Duchenne Muscular Dystrophy (DMD), sponsored by Sarepta Therapeutics, Inc.. Completed at 37 sites in United States. Open to male participants aged 7 Years to 16 Years. Per ClinicalTrials.gov, last updated 2021-01-25.

Sponsored by Sarepta Therapeutics, Inc. · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
109
Allocation
Non-randomized
Ages
7 Years to 16 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne — none open to participants now, none under way, none of them phase 3. eteplirsen · Muscular Dystrophy, Duchenne.

Enrollment
2nd of 11
109 · median 15
Started
2014
with 1 other
Phase 3
2 of 11
none open now
Registered
5th of 11
by date
Lead sponsor
9 of 11
Sarepta Therapeutics, Inc.

Among the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne, this one is the 2nd largest by enrollment, is one of 2 that started in 2014, is one of 2 in phase 3, and was the 5th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

None of the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne is open now. The open studies under Muscular Dystrophy, Duchenne, anywhere →

About eteplirsen

eteplirsen: first FDA approval 2016 (EXONDYS 51). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Muscular Dystrophy, Duchenne studies recruiting now, 30 (45%) set no upper age limit and 34 (52%) stop at 75 or younger; 59 take children under 18; 11 take healthy volunteers.

This study: 7 Years to 16 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing eteplirsen in Muscular Dystrophy, Duchenne as a file.
02

Study summary

The main objective of this study is to provide evidence of efficacy of eteplirsen (AVI-4658) in Duchenne muscular dystrophy (DMD) patients that are amenable to skipping exon 51. Additional objectives include evaluation of safety, biomarkers and the long-term effects of eteplirsen up to 96 weeks, followed by a safety extension (not to exceed 48 weeks).

Read the detailed description

This is an open-label, multi-center study to evaluate the efficacy and safety of eteplirsen in patients with genotypically confirmed Duchenne muscular dystrophy (DMD) with genetic deletions amenable to exon 51 skipping (treated group), with a concurrent control arm of DMD patients not amenable to exon 51 skipping (untreated group). Following primary efficacy endpoints, dosing will continue to week 144 to evaluate the long term effects of eteplirsen.

Patients in the treated group will receive once weekly intravenous (IV) infusions of 30 mg/kg Eteplirsen for 96 weeks, followed by a safety extension (not to exceed 48 weeks). Patients in the untreated group will not receive treatment.

Clinical efficacy will be assessed at regularly scheduled study visits, including functional tests such as the six minute walk test. Patients in the treated group will undergo a muscle biopsy at Baseline and a second muscle biopsy over the course of the study. Patients in the untreated group will not undergo muscle biopsy.

Safety, including adverse event monitoring and routine laboratory assessments, will be continuously monitored for all patients.

03

Conditions studied

  • Duchenne Muscular Dystrophy (DMD)

Keywords

  • DMD, Duchenne, Eteplirsen, dystrophy, dystrophin, exon 51
04

Who can participate

Ages eligible
7 Years to 16 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male 7-16 years old
  • Diagnosed with DMD, genotypically confirmed
  • Stable dose of for at least 24 weeks
  • Have intact right and left alternative upper muscle groups
  • Mean 6MWT greater than 300m (primary analysis on 300 to 450 meters)
  • Stable pulmonary and cardiac function: predicted FVC equal to or greater than 50% and of greater than 50%

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with drisapersen or any other RNA antisense agent or any gene therapy within the last 6 months
  • Participation in any other DMD interventional clinical study within 12 weeks
  • Major surgery within 3 months
  • Presence of other illness
  • Major change in the physical therapy regime within 3 months

Other inclusion/exclusion criteria apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
109 participants (actual)

Study arms

  • Experimental
    Treated Group

    Approximately 80 patients with genotypically confirmed Duchenne muscular dystrophy (DMD) with genetic deletions amenable to treatment by exon 51 skipping will receive 30 mg/kg of eteplirsen weekly for 96 weeks, followed by a safety extension (not to exceed 48 weeks).

    Drug: eteplirsen

  • No intervention
    Untreated Group

    Approximately 30 DMD patients not amenable to exon 51 skipping will not receive eteplirsen.

Interventions

  • Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks, followed by a safety extension (not to exceed 48 weeks).

    Also known as: AVI-4658, EXONDYS 51®

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the 6 Minute Walk Test (6MWT) Distance at Week 96

    6MWT was performed by standardized procedures for all participants. Participants were asked to walk a set course of 25 meters for 6 minutes (timed), and the distance walked (in meters) was recorded. Change from baseline in 6MWT distance at Week 96 was reported.

    Time frame: Baseline, Week 96

Secondary outcomes

  1. Change From Baseline in Dystrophin Protein Levels Determined by Western Blot at Week 96

    Change from baseline in dystrophin protein levels (in muscle biopsy samples) were determined by Western blot. For each time point, 2 blocks of tissues were analyzed by Western blot, each with 2 replicates of gels to determine the dystrophin level as compared to a healthy individual (Percent Normal). The block average value from 2 replicate gels was computed. The overall average was calculated as the mean of the block average values. The overall average values were used for all analyses. In case only 1 gel was available for a block, then that value was used as the block average value.

    Time frame: Baseline, Week 96

  2. Number of Participants Having Ability to Rise Independently From the Floor Determined Based on North Star Ambulatory Assessment (NSAA) at Week 96

    NSAA is a clinician-administered scale that rates participant performance on 17-items and included assessments of abilities such as 10-meter walk/run, rising from a sit to stand, standing on 1 leg, climbing a box step, descending a box step, rising from lying to sitting, rising from the floor, lifting the head, standing on heels, and jumping. For all activities, participants were graded as follows: 0 = unable to achieve goal independently; 1 = modified method but achieves goal independent of physical assistance from another and 2 = normal, no obvious modification of activity. Number of participants having ability to rise independently from the floor indicated by a NSAA Rise from floor sub score greater than 0 (unable to achieve goal independently) was reported.

    Time frame: Week 96

  3. Number of Participants Who Lost Ambulation (LOA) by Week 96

    Number of participants who lost ambulation (LOA) by Week 96 was reported. Participant were considered non-ambulatory if each of the 3 conditions below were met: NSAA walk subscore was "0" (unable to achieve goal independently) on 2 consecutive days within a visit or NSAA was not done due to reason related to non-ambulation; 6MWT was not done with any reason related to permanent non-ambulation; and no later data showing this participant was still ambulatory. This was not required if non ambulatory status occurred at the time of early withdrawal or at the end of Week 96 assessment. NSAA is a 17-item scale to assess the participant's abilities; total score range from 0 (if all the activities are failed) to 34 (if all the activities are achieved) with higher scores indicating better performance on the assessment/ fully-independent function.

    Time frame: Up to Week 96

  4. Change From Baseline in Forced Vital Capacity Percent (FVC%) Predicted at Weeks 96

    FVC is the total amount of air exhaled during the forced expiratory volume test that is measured during spirometry; and is the most important measurement of lung function. This test requires participant to breath into a tube connected to a machine that measures the amount of air that can be moved in and out of the lungs after taking an inhaled bronchodilator medicine which is used to dilate participant's bronchial (breathing) tubes. Percent of predicted FVC = (observed value) / (predicted value) \* 100%.

    Time frame: Baseline, Week 96

  5. Change From Baseline in North Star Ambulatory Assessment (NSAA) Total Scores at Week 96

    NSAA is a clinician-administered scale that rates participant performance on 17-items and included assessments of abilities such as 10-meter walk/run, rising from a sit to stand, standing on 1 leg, climbing a box step, descending a box step, rising from lying to sitting, rising from the floor, lifting the head, standing on heels, and jumping. Participant were graded as follows: 0 = unable to achieve goal independently; 1 = modified method but achieves goal independent of physical assistance from another and 2 = normal, no obvious modification of activity. NSAA total score was derived by summing the scores for all the individual items and range from 0 (if all the activities are failed) to 34 (if all the activities are achieved) with higher scores indicating better performance on the assessment/ fully-independent function.

    Time frame: Baseline, Week 96

  6. Change From Baseline in Dystrophin Intensity Levels Determined by Immunohistochemistry (IHC) at Week 96

    Change from baseline in dystrophin intensity levels (in muscle biopsy samples) was determined by Immunohistochemistry.

    Time frame: Baseline, Week 96

07

Results

Posted Jul 1, 2020

Participant flow

The study was conducted at 40 sites in the United States.

Participant flow — Overall Study
MilestoneEteplirsen 30 mg/kgUntreated Control Group (Non-exon 51 Amenable Participants)
Started7930
Completed7815
Not completed115
Withdrew: Participants enrolled into another study011
Withdrew: Withdrawal by subject14

Outcome measures

PrimaryChange From Baseline in the 6 Minute Walk Test (6MWT) Distance at Week 96

6MWT was performed by standardized procedures for all participants. Participants were asked to walk a set course of 25 meters for 6 minutes (timed), and the distance walked (in meters) was recorded. Change from baseline in 6MWT distance at Week 96 was reported.

Time frame:
Baseline, Week 96
Reported as:
Mean · meters
Change From Baseline in the 6 Minute Walk Test (6MWT) Distance at Week 96
metersEteplirsen 30 mg/kgUntreated Control Group (Non-exon 51 Amenable Participants)
Change From Baseline in the 6 Minute Walk Test (6MWT) Distance at Week 96-117.91 ± 128.488-133.56 ± 129.333
SecondaryChange From Baseline in Dystrophin Protein Levels Determined by Western Blot at Week 96

Change from baseline in dystrophin protein levels (in muscle biopsy samples) were determined by Western blot. For each time point, 2 blocks of tissues were analyzed by Western blot, each with 2 replicates of gels to determine the dystrophin level as compared to a healthy individual (Percent Normal). The block average value from 2 replicate gels was computed. The overall average was calculated as the mean of the block average values. The overall average values were used for all analyses. In case only 1 gel was available for a block, then that value was used as the block average value.

Time frame:
Baseline, Week 96
Reported as:
Mean · Percent Normal Dystrophin Protein Level
Change From Baseline in Dystrophin Protein Levels Determined by Western Blot at Week 96
Percent Normal Dystrophin Protein LevelEteplirsen 30 mg/kg
Change From Baseline in Dystrophin Protein Levels Determined by Western Blot at Week 960.516 ± 0.7236
SecondaryNumber of Participants Having Ability to Rise Independently From the Floor Determined Based on North Star Ambulatory Assessment (NSAA) at Week 96

NSAA is a clinician-administered scale that rates participant performance on 17-items and included assessments of abilities such as 10-meter walk/run, rising from a sit to stand, standing on 1 leg, climbing a box step, descending a box step, rising from lying to sitting, rising from the floor, lifting the head, standing on heels, and jumping. For all activities, participants were graded as follows: 0 = unable to achieve goal independently; 1 = modified method but achieves goal independent of physical assistance from another and 2 = normal, no obvious modification of activity. Number of participants having ability to rise independently from the floor indicated by a NSAA Rise from floor sub score greater than 0 (unable to achieve goal independently) was reported.

Time frame:
Week 96
Reported as:
Count of participants · Participants
Number of Participants Having Ability to Rise Independently From the Floor Determined Based on North Star Ambulatory Assessment (NSAA) at Week 96
ParticipantsEteplirsen 30 mg/kgUntreated Control Group (Non-exon 51 Amenable Participants)
Number of Participants Having Ability to Rise Independently From the Floor Determined Based on North Star Ambulatory Assessment (NSAA) at Week 96333
SecondaryNumber of Participants Who Lost Ambulation (LOA) by Week 96

Number of participants who lost ambulation (LOA) by Week 96 was reported. Participant were considered non-ambulatory if each of the 3 conditions below were met: NSAA walk subscore was "0" (unable to achieve goal independently) on 2 consecutive days within a visit or NSAA was not done due to reason related to non-ambulation; 6MWT was not done with any reason related to permanent non-ambulation; and no later data showing this participant was still ambulatory. This was not required if non ambulatory status occurred at the time of early withdrawal or at the end of Week 96 assessment. NSAA is a 17-item scale to assess the participant's abilities; total score range from 0 (if all the activities are failed) to 34 (if all the activities are achieved) with higher scores indicating better performance on the assessment/ fully-independent function.

Time frame:
Up to Week 96
Reported as:
Count of participants · Participants
Number of Participants Who Lost Ambulation (LOA) by Week 96
ParticipantsEteplirsen 30 mg/kgUntreated Control Group (Non-exon 51 Amenable Participants)
Number of Participants Who Lost Ambulation (LOA) by Week 96121
SecondaryChange From Baseline in Forced Vital Capacity Percent (FVC%) Predicted at Weeks 96

FVC is the total amount of air exhaled during the forced expiratory volume test that is measured during spirometry; and is the most important measurement of lung function. This test requires participant to breath into a tube connected to a machine that measures the amount of air that can be moved in and out of the lungs after taking an inhaled bronchodilator medicine which is used to dilate participant's bronchial (breathing) tubes. Percent of predicted FVC = (observed value) / (predicted value) \* 100%.

Time frame:
Baseline, Week 96
Reported as:
Mean · Percentage of predicted FVC
Change From Baseline in Forced Vital Capacity Percent (FVC%) Predicted at Weeks 96
Percentage of predicted FVCEteplirsen 30 mg/kgUntreated Control Group (Non-exon 51 Amenable Participants)
Change From Baseline in Forced Vital Capacity Percent (FVC%) Predicted at Weeks 96-3.413 ± 12.4011-2.461 ± 9.6000
SecondaryChange From Baseline in North Star Ambulatory Assessment (NSAA) Total Scores at Week 96

NSAA is a clinician-administered scale that rates participant performance on 17-items and included assessments of abilities such as 10-meter walk/run, rising from a sit to stand, standing on 1 leg, climbing a box step, descending a box step, rising from lying to sitting, rising from the floor, lifting the head, standing on heels, and jumping. Participant were graded as follows: 0 = unable to achieve goal independently; 1 = modified method but achieves goal independent of physical assistance from another and 2 = normal, no obvious modification of activity. NSAA total score was derived by summing the scores for all the individual items and range from 0 (if all the activities are failed) to 34 (if all the activities are achieved) with higher scores indicating better performance on the assessment/ fully-independent function.

Time frame:
Baseline, Week 96
Reported as:
Mean · Unit on scale
Change From Baseline in North Star Ambulatory Assessment (NSAA) Total Scores at Week 96
Unit on scaleEteplirsen 30 mg/kgUntreated Control Group (Non-exon 51 Amenable Participants)
Change From Baseline in North Star Ambulatory Assessment (NSAA) Total Scores at Week 96-7.23 ± 5.173-8.44 ± 9.812
SecondaryChange From Baseline in Dystrophin Intensity Levels Determined by Immunohistochemistry (IHC) at Week 96

Change from baseline in dystrophin intensity levels (in muscle biopsy samples) was determined by Immunohistochemistry.

Time frame:
Baseline, Week 96
Reported as:
Mean · Percent dystrophin positive fibers
Change From Baseline in Dystrophin Intensity Levels Determined by Immunohistochemistry (IHC) at Week 96
Percent dystrophin positive fibersEteplirsen 30 mg/kg
Change From Baseline in Dystrophin Intensity Levels Determined by Immunohistochemistry (IHC) at Week 960.030 ± 0.0360

Adverse events

Collected over From start of study drug administration to Week 144. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eteplirsen 30 mg/kg0/79 (0%)11/79 (13.9%)78/79 (98.7%)
Untreated Control Group (Non-exon 51 Amenable Participants)0/30 (0%)2/30 (6.7%)24/30 (80%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventEteplirsen 30 mg/kgUntreated Control Group (Non-exon 51 Amenable Participants)
AbasiaGeneral disorders0/791/30
Lymphadenitis viralInfections and infestations0/791/30
Femoral neck fractureInjury, poisoning and procedural complications2/790/30
Femur fractureInjury, poisoning and procedural complications1/790/30
Hip fractureInjury, poisoning and procedural complications1/790/30
Pneumonitis chemicalInjury, poisoning and procedural complications1/790/30
ArrhythmiaCardiac disorders1/790/30
MyocarditisCardiac disorders1/790/30
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/790/30
AspirationRespiratory, thoracic and mediastinal disorders1/790/30
Most frequent other events
Showing 10 of 61
Most frequent other events
EventEteplirsen 30 mg/kgUntreated Control Group (Non-exon 51 Amenable Participants)
HeadacheNervous system disorders40/791/30
VomitingGastrointestinal disorders39/790/30
CoughRespiratory, thoracic and mediastinal disorders36/791/30
Back painMusculoskeletal and connective tissue disorders29/791/30
NasopharyngitisInfections and infestations29/793/30
Pain in extremityMusculoskeletal and connective tissue disorders26/792/30
Procedural painInjury, poisoning and procedural complications25/790/30
Nasal congestionRespiratory, thoracic and mediastinal disorders25/791/30
Upper respiratory tract infectionInfections and infestations25/791/30
ContusionInjury, poisoning and procedural complications24/791/30

Baseline characteristics

Consisted of all participants who received at least 1 dose of eteplirsen in the eteplirsen-treated group or had at least 1 post-baseline safety assessment in the untreated group.Comparisons between the eteplirsen-treated and the untreated group were not to be performed due to the small number of subjects and differences in the population groups.

Age, Continuous
Age, Continuous(Years)Eteplirsen 30 mg/kgUntreated Control Group (Non-exon 51 Amenable Participants)Total
Mean9.1 ± 2.048.8 ± 1.769.0 ± 1.96
Sex: Female, Male
Sex: Female, Male(Participants)Eteplirsen 30 mg/kgUntreated Control Group (Non-exon 51 Amenable Participants)Total
Female000
Male7930109
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Eteplirsen 30 mg/kgUntreated Control Group (Non-exon 51 Amenable Participants)Total
Hispanic or Latino7613
Not Hispanic or Latino712495
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Eteplirsen 30 mg/kgUntreated Control Group (Non-exon 51 Amenable Participants)Total
American Indian or Alaska Native000
Asian516
Native Hawaiian or Other Pacific Islander202
Black or African American202
White672693
More than one race000
Unknown or Not Reported336
Region of Enrollment
Region of Enrollment(Participants)Eteplirsen 30 mg/kgUntreated Control Group (Non-exon 51 Amenable Participants)Total
United States7930109
08

Study locations

37 sites
  • Neuromuscular Research Center
    Phoenix, Arizona 85028, United States
  • David Geffen School of Medicine at UCLA
    Los Angeles, California 90095, United States
  • University of California, Davis Medical Center
    Sacramento, California 95817, United States
  • Rady Children's Hospital, U.C. San Diego
    San Diego, California 92130, United States
  • Stanford University School of Medicine/Medical Center
    Stanford, California 94305, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Connecticut Children's Medical Center
    Hartford, Connecticut 06106, United States
  • Children's National Health System
    Washington, District of Columbia 20010, United States
  • The University of Florida, Powell Gene Therapy Center
    Gainesville, Florida 32610, United States
  • NW FL Clinical Research Group, LLC
    Gulf Breeze, Florida 32561, United States
  • Nemours Children's Hospital
    Orlando, Florida 32827, United States
  • Rare Disease Research Center
    Atlanta, Georgia 30318, United States
  • Emory University
    Atlanta, Georgia 30324, United States
  • Ann and Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • University of Iowa Children's Hospital
    Iowa City, Iowa 52242, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Kennedy Krieger Institute
    Baltimore, Maryland 21205, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Children's Hospital Boston
    Boston, Massachusetts 02115, United States
  • Children's Hospital of Michigan
    Detroit, Michigan 48201, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • St. Louis Children's Hospital
    Saint Louis, Missouri 63110, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • University of Rochester Clinical Research Center
    Rochester, New York 14642, United States
  • Levine Childrens Hospital, Carolinas Medical Center
    Charlotte, North Carolina 28207, United States
  • Cincinnati Children's Hospital Medical Center (CCHMC)
    Cincinnati, Ohio 45229, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Shriners Hospital for Children
    Portland, Oregon 97239, United States
  • Penn State Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Children's Hospital of Pittsburgh of UPMC
    Pittsburgh, Pennsylvania 15224, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • The University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • University of Utah
    Salt Lake City, Utah 84132, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
09

References and documents

Publications

  • Brogna C, Coratti G, Pane M, Ricotti V, Messina S, D'Amico A, Bruno C, Vita G, Berardinelli A, Mazzone E, Magri F, Ricci F, Mongini T, Battini R, Bello L, Pegoraro E, Baranello G, Previtali SC, Politano L, Comi GP, Sansone VA, Donati A, Bertini E, Muntoni F, Goemans N, Mercuri E; on behalf on the International DMD group. Long-term natural history data in Duchenne muscular dystrophy ambulant patients with mutations amenable to skip exons 44, 45, 51 and 53. PLoS One. 2019 Jun 25;14(6):e0218683. doi: 10.1371/journal.pone.0218683. eCollection 2019. Erratum In: PLoS One. 2019 Jul 31;14(7):e0220714. doi: 10.1371/journal.pone.0220714. PubMed 31237898 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2014 to primary completion in Jun 2019, 54 months.

Results were first posted in Jul 2020, 1 year after primary completion.

Of 26 phase 3 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 73. This study's 54 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2014
First posted
Oct 2, 2014
StartActual
Nov 17, 2014
Primary completionActual
Jun 14, 2019
CompletionActual
Jun 14, 2019
Results first posted
Jul 1, 2020
Last update
Jan 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02255552
Responsible party
Sponsor
First posted
Oct 2, 2014
Start date
Nov 17, 2014
Primary completion
Jun 14, 2019
Completion
Jun 14, 2019
Results posted
Jul 1, 2020
Last update
Jan 25, 2021

Study contacts

Medical Director
study director · Sarepta Therapeutics, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eteplirsen

Start the discussion